NIH R01 · 2024
Reprogramming myogenic regulatory factors in RMS to promote differentiation and halt growth
Summary Rhabdomyosarcoma (RMS) accounts for 3-4% of all pediatric cancers, with less than a 30% overall 5-year survival rate for children diagnosed with metastatic RMS. Sarcoma patients also experience higher rates of morbidity and mortality than other cancer patients, and this is particularly evident in children. As a result of their therapies, 42% of childhood cancer survivors experience severe, disabling, or life threatening conditions, including secondary tumors. Thus, there is clearly a need to develop new, more targeted treatment strategies for pediatric tumors such as RMS; treatments that inhibit tumor progression yet confer limited side effects. In many cancers, embryonic programs,…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.